AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.
| Revenue (Most Recent Fiscal Year) | $234.60M |
| Net Income (Most Recent Fiscal Year) | $-13.23M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 310.73 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.86 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 106.41 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -11.46% |
| Net Margin (Trailing 12 Months) | 82.37% |
| Return on Equity (Trailing 12 Months) | 112.00% |
| Return on Assets (Trailing 12 Months) | 2.20% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.58 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.58 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.34 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.11 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.46 |
| Diluted Earnings per Share (Trailing 12 Months) | $5.37 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 29.90M |
| Free Float | 20.48M |
| Market Capitalization | $1.39B |
| Average Volume (Last 20 Days) | 0.58M |
| Beta (Past 60 Months) | 0.76 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 31.50% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |